–(BUSINESS WIRE)–Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwid…
Tag: AMD
Lpath Grants Pfizer Exclusive Option for Worldwide License for AMD Treatment iSONEP
Lpath, Inc. has entered into an agreement providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEP Lpath’s lead monoclonal antibody product candidate, which is being evaluated for the treatment of wet age-…
Lifestyle Changes May Avert Age-Related Macular Degeneration
Modifying lifestyles might reduce the risk for early age-related macular degeneration as much as 3-fold, lowering the risk for advanced macular degeneration in a person’s lifetime and societal costs. Medscape Medical News
Avastin/Lucentis Update 44: United Kingdom Closer to Allowing Avastin for AMD
While the U.S. comes closer to showing the equivalency of Avastin to Lucentis for treating the wet form of age-related macular degeneration, when the CATT Study (Comparisons of Age-Related Macular Degeneration Treatments Trials) results become public, …
Omega 3 Rich Foods Protect Seniors From Age-Related Macular Degeneration (AMD)
Seniors whose diets are rich in omega 3 fatty acids have a significantly lower risk of developing AMD (age-related macular degeneration) compared to other people of the same age, scientists revealed in the journal Ophthalmology. Good sources of Omega 3…
Can Omega-3 Fatty Acids in Fish Prevent Age-Related Macular Degeneration?
The December 2010 issue of Ophthalmology reports on a study of 2520 residents of Salisbury, Maryland, aged 65 to 84 years to determine the relationship between fish and shellfish consumption and age-related macular degeneration (AMD). Full Story →
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: 1-year Outcomes of a Prospective, Double-masked Randomised Clinical Trial
This study compares two drugs in the treatment of age-related macular degeneration. Eye
VEGF Trap-Eye Treats Macular Degeneration
VEGF Trap-Eye is a new injectable medication that blocks VEGF for the treatment of wet macular degeneration. It may be as good as Lucentis, but not given as often.
Update on Combination Therapy in Wet Age-related Macular Degeneration
Which combination of drugs are considered to be most effective in treating wet ARMD? This new study looks at the therapeutic options. Expert Review of Ophthalmology Full Story →
Popular Science names VisionCare’s Implantable Miniature Telescope for AMD ‘Best of What’s New’ 2010
VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, today announced the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), designed to improve vision in patients with end-stage age-related macular degeneration (AMD) is named “Best of What’s New” 2010…
Treat and Extend Regimen Saves Money and Injections for AMD
Full Story →
The Use of Gene Therapy in Treating Retinitis Pigmentosa and Dry AMD
A short while ago, I received a message from someone I did not know, who said that he enjoyed the writeups on my online Journal and was wondering if I might be interested in writing about the use of gene therapy as an approach to vision restoration. Si…
Telescope Implant Improves Vision in Macular Degeneration
People with end-stage age-related macular degeneration (AMD) have improved visual acuity and quality of life after receiving an intraocular implant containing a tiny telescope in 1 eye, new research shows. An ophthalmologist who participated in the c…
Telescope Implant Improves Vision in Macular Degeneration
A recently approved intraocular implant device containing a telescope is for select patients with end-stage age-related macular degeneration. Medscape Medical News
Driving Ability Improved After Ranibizumab Therapy in Patients With Macular Degeneration
Monthly intravitreal injections with the VEGF antagonist ranibizumab reduces self-reported difficulty driving in patients with age-related macular degeneration. Medscape Medical News
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Status: Recruiting,
Condition Summary: Age-Related Maculopathy; Age-Related Maculopathies; Eye Diseases; Retinal Degeneration; Macular Degeneration
Drugs for macular degeneration
(Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the therapy of a…
Do Anti-VEGF Injections Increase the Risk of Stroke or Heart Attack?
By Dr. Ari WeitznerSome have speculated that the anti-VEGF injections we give to macular degeneration patients may get into the bloodstream and have adverse vascular effects. According to a recently released retrospective study (appearing in the October 2010 issue of the Archives of Ophthalmology), using vascular endothelial growth factor (VEGF) blockers to treat neovascular age-related […]
AMD Update 13: Retinal Procedures on the Rise
A new study, just published in the October issue of Archives of Ophthalmology and reported by Ophthalmology Web, MedPage Today, and Medscape Medical News, shows that among those in the Medicare population (age 65 plus), treatments for retinal con…
Safety & Efficacy Study of the IRay System in Patients With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Status: Recruiting,
Condition Summary: AMD; Wet AMD; Age-Related Macular Degeneration; Wet Age-Related Macular Degeneration; Macular Degeneration; Eye Diseases; Retinal Diseases